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Patients with advanced-stage Hodgkin lymphoma (HL) receiving
intensive treatment with escalated BEACOPP (bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine, procarbazine,
prednisone) (eBEACOPP) have excellent outcomes [1, 2]. However,
late effects such as second primary malignancies (SPM) and
infertility represent ongoing concerns [3, 4]. Novel approaches
using an eBEACOPP backbone, therefore, aim at reducing toxicity
without compromising efficacy. The BrECAPP (brentuximab
vedotin, etoposide, cyclophosphamide, doxorubicin, procarbazine,
prednisone) and BrECADD (brentuximab vedotin, etoposide,
cyclophosphamide, doxorubicin, dacarbazine, dexamethasone)
protocols were investigated in a randomized phase II study
including patients with newly diagnosed advanced-stage classical
HL (cHL). Both regimens combine eBEACOPP-based chemother-
apy with the CD30-directed antibody-drug conjugate brentuximab
vedotin (BV). Response rates were similar to standard eBEACOPP
and especially the BrECADD protocol was associated with reduced
acute toxicity [5].
The major objectives of the present follow-up analysis of the
study were progression-free survival (PFS) and overall survival (OS)
at 3 years. Patterns of cHL recurrence, the occurrence of SPM, and
causes of death were also evaluated. PFS and OS were analyzed
using the Kaplan–Meier method. PFS was defined as the time
between randomization and progression or relapse of cHL or
death from any cause and was censored at the date of last
information on the disease status. OS was defined as the time
between randomization and death from any cause and was
censored at the date of last information for surviving patients.
Characteristics of cHL recurrence, SPM, and causes of death were
analyzed descriptively. Study design, inclusion criteria, endpoints,
procedures, and treatment have been published elsewhere [5].
The study was conducted in accordance with the Declaration of
Helsinki and was approved by the review boards of the
participating sites. The study was registered at www.clinicaltrials.
gov as #NCT01569204.
A total of 104 patients with advanced-stage cHL aged 18–60
years were enrolled at 20 sites in Germany. Baseline characteristics
have been reported previously. In brief, 63 patients (61%) were
male, the median age was 29 years (range: 18–60 years), and 86
patients (82%) presented with stage III/IV disease [5]. Baseline
characteristics were thus consistent with the randomized German
Hodgkin Study Group (GHSG) HD15 and HD18 studies for
advanced-stage HL [1, 2]. Three patients were not included in
the outcome analyses since they did not receive study treatment
(n= 2) or terminated study treatment after the advanced-stage
disease had been disconfirmed (n= 1). Hence, the present
analysis included 101 patients who had been treated with 6
cycles of BrECAPP (n= 49) or BrECADD (n= 52); 13 patients
(BrECAPP: 7 patients; BrECADD: 6 patients) with residual lym-
phoma ≥2.5 cm and a positive positron emission tomography
(PET) at the end of systemic therapy had an indication for
consolidation radiotherapy [5].
After a median observation time of 34 months (interquartile
range: 28.7–39.5 months), the 3-year PFS estimates were 90.2%
(95%-CI: 80.9–99.5%) with BrECAPP and 89.7% (95%-CI:
81.0–98.3%) with BrECADD (Fig. 1A, Table 1). In the randomized
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ECHELON-1 study for newly diagnosed stage III/IV cHL, the 3-year
PFS among patients aged younger than 60 years who had
treatment with the BV-containing A-AVD (BV, doxorubicin,
vinblastine, dacarbazine) regimen was 84.9% (95%-CI:
81.6–87.7%) [6]. Disease control with BrECAPP and BrECADD was
thus at least similar to and possibly better than with A-AVD.
Eight patients treated in the present study experienced primary
disease progression (n= 3) or relapse of cHL (n= 5). Sites of initial
bulky disease were involved in 6 cases. The median time from the
end of BrECAPP or BrECADD therapy to disease progression or
relapse was 13 months (range: 1–26 months). Second-line treatment
consisted of high-dose chemotherapy and autologous stem cell
transplantation in all cases. No study participant developed an SPM
(Table 1). This is notable since older analyses had indicated an
increased risk especially for the development of therapy-related
acute myeloid leukemia and myelodysplastic syndrome (t-AML/
MDS) after 8 cycles of eBEACOPP [3, 7, 8]. However, the current
GHSG standard of care for advanced-stage HL consisting of 4 or 6
cycles of eBEACOPP stratified by PET after 2 cycles of chemotherapy
appears to be associated with a significantly lower risk. The t-AML/
MDS incidence among patients who had received 4 or 6 cycles of
eBEACOPP within the HD15 and HD18 studies was lower than 1%
[1, 2]. Unlike second hematologic malignancies that usually occur
within the first years after HL treatment, the risk for the
development of second solid tumors after BrECAPP and BrECADD
cannot be estimated yet [7, 9, 10]. Longer follow-up is required since
second solid tumors are typically diagnosed many years after HL
treatment and the risk for the occurrence of such malignancies
seems to be elevated for decades [11, 12].
Two patients who had treatment in the present study died
during observation. Deaths occurred 15 and 24 months after the
end of systemic study treatment. One of the deaths was due to
cHL (Table 1). A low rate of HL-related deaths was also observed in
other studies comprising patients with advanced-stage HL, e.g.,
the HD15 and HD18 studies using eBEACOPP and the RATHL study
using ABVD [1, 2, 13].
The 3-year OS estimates were 100% with BrECAPP and 95.4%
(95% CI: 89.2–100%) with BrECADD (Fig. 1B, Table 1). In the
ECHELON-1 study, the 2-year OS among patients treated with
A-AVD was 96.6% [14].
The present analysis has some limitations. Given the mostly
young age at diagnosis and the high cure rate, quality of life (QoL)
Fig. 1 Outcomes of patients treated with BrECAPP and BrECADD. A) Progression-free survival after treatment with BrECAPP and BrECADD;
B) Overall survival after treatment with BrECAPP and BrECADD.
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Overall survival 100% 95.4%
(89.2–100%)
Hodgkin lymphoma eventsa
Any Hodgkin lymphoma event 4 (8%) 4 (8%)
Progressionb 0 3 (6%)
Relapsec 4 (8%) 1 (2%)
Number of Hodgkin lymphoma events
1 4 (8%) 2 (4%)
2 0 2 (4%)
Second-line treatment
High-dose chemotherapy and autologous stem
cell transplantation
4 (8%) 4 (8%)
Causes of death
Any event 0 2 (4%)
Hodgkin lymphoma 0 1 (2%)
Accident 0 1 (2%)
Second primary malignancies
Any event 0 0
Data are median, % (95%-CI), or n (%). Only patients eligible for efficacy
analyses are shown; 3 of 104 patients were excluded because they did not
receive any study treatment (n= 2) or terminated treatment due to
disconfirmation of advanced-stage disease (n= 1).
BrECAPP brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin,
procarbazine, prednisone, BrECADD brentuximab vedotin, etoposide,
cyclophosphamide, doxorubicin, dacarbazine, dexamethasone.
aDefined as biopsy-proven disease progression or relapse of cHL.
bDefined as the occurrence of new lesions during treatment or at least 1
known lesion that increased by more than 25% in diameter during
treatment or within 3 months after the end of systemic study treatment.
cDefined as the appearance of new lesions or the reappearance of initial
lesions at least 3 months after the end of systemic study treatment.















aspects and fertility issues play an important role in the
management and the choice of treatment in HL patients [4, 15].
However, valid analyses on QoL and fertility in individuals who
had received BrECAPP or BrECADD could not be performed due to
the inability to obtain sufficient data.
Taken together, the present update analysis of a randomized
phase II study investigating the BV-containing eBEACOPP variants
BrECAPP and BrECADD in the first-line treatment of advanced-
stage cHL confirms the safety and efficacy of these protocols. The
BrECADD regimen had been chosen to challenge eBEACOPP in the
randomized GHSG HD21 study (NCT02661503) that recently
finished recruitment for the cohort of patients aged 60 years or
younger. Results of this trial are pending. Results were in part
presented at the EHA 2021 Virtual Congress, June 9 to 17, 2021.
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